{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:40:53Z","timestamp":1791484853813,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1124\/dmd.123.001633","type":"journal-article","created":{"date-parts":[[2024,5,29]],"date-time":"2024-05-29T19:30:17Z","timestamp":1717011017000},"page":"765-774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Human Pharmacokinetic and CYP3A Drug\u2013Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment"],"prefix":"10.1016","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5784-3074","authenticated-orcid":false,"given":"Jesse","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuxi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.123.001633_bib1","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1124\/dmd.115.066845","article-title":"Prediction of drug-drug interactions arising from CYP3A induction using a physiologically based dynamic model","volume":"44","author":"Almond","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0009-9236(96)90018-1","article-title":"Rifampin drastically reduces plasma concentrations and effects of oral midazolam","volume":"59","author":"Backman","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001633_bib3","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1002\/jps.22709","article-title":"A convenient method to measure blood-plasma concentration ratio using routine plasma collection in in vivo pharmacokinetic studies","volume":"100","author":"Berezhkovskiy","year":"2011","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.123.001633_bib4","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1021\/acs.molpharmaceut.8b00688","article-title":"Evaluating the utility of canine Mdr1 knockout Madin-Darby canine kidney I cells in permeability screening and efflux substrate determination","volume":"15","author":"Chen","year":"2018","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.123.001633_bib5","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.xphs.2018.10.011","article-title":"Improving confidence in the determination of free fraction for highly bound drugs using bidirectional equilibrium dialysis","volume":"108","author":"Chen","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.123.001633_bib6","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tips.2020.03.004","article-title":"Improving the accuracy of predicted human pharmacokinetics: lessons learned from the AstraZeneca drug pipeline over two decades","volume":"41","author":"Davies","year":"2020","journal-title":"Trends Pharmacol Sci"},{"key":"10.1124\/dmd.123.001633_bib7","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1365-2125.2008.03309.x","article-title":"4beta-hydroxycholesterol as an endogenous marker for CYP3A4\/5 activity. Stability and half-life of elimination after induction with rifampicin","volume":"67","author":"Diczfalusy","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib8","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.123.001633_bib9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1124\/dmd.116.074476","article-title":"Examination of the human cytochrome P4503A4 induction potential of PF-06282999, an irreversible myeloperoxidase inactivator: integration of preclinical, in silico, and biomarker methodologies in the prediction of the clinical outcome","volume":"45","author":"Dong","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib10","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1517\/17425255.2010.516251","article-title":"Evaluation of models for predicting drug-drug interactions due to induction","volume":"6","author":"Fahmi","year":"2010","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.123.001633_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s00280-020-04064-6","article-title":"Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation","volume":"85","author":"Fan","year":"2020","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib12","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1124\/dmd.123.001633_bib13","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/tpj.2012.46","article-title":"Pharmacogenetic and pharmacokinetic aspects of CYP3A induction by efavirenz in HIV patients","volume":"13","author":"Habtewold","year":"2013","journal-title":"Pharmacogenomics J"},{"key":"10.1124\/dmd.123.001633_bib14","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1021\/mp0600900","article-title":"Prediction and mechanistic interpretation of human oral drug absorption using MI-QSAR analysis","volume":"4","author":"Iyer","year":"2007","journal-title":"Mol Pharm"},{"key":"10.1124\/dmd.123.001633_bib15","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1208\/s12248-009-9099-y","article-title":"Population-based mechanistic prediction of oral drug absorption","volume":"11","author":"Jamei","year":"2009","journal-title":"AAPS J"},{"key":"10.1124\/dmd.123.001633_bib16","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.3390\/jcm10163711","article-title":"Dyslipidemia management in patients with coronary artery disease. Data from the POLASPIRE survey","volume":"10","author":"Jankowski","year":"2021","journal-title":"J Clin Med"},{"key":"10.1124\/dmd.123.001633_bib17","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/psp.2013.41","article-title":"Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development","volume":"2","author":"Jones","year":"2013","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib18","doi-asserted-by":"crossref","DOI":"10.1124\/dmd.121.000784","article-title":"Application of empirical scalars to enable early prediction of human hepatic clearance using IVIVE in drug discovery: an evaluation of 173 drugs","author":"Jones","year":"2022","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib19","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/bcp.12425","article-title":"Validation of 4\u03b2-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects","volume":"78","author":"Kasichayanula","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib20","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1124\/dmd.118.081927","article-title":"Considerations from the Innovation and Quality Induction Working Group in response to drug-drug interaction guidances from regulatory agencies: focus on CYP3A4 mRNA in vitro response thresholds, variability, and clinical relevance","volume":"46","author":"Kenny","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib21","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1124\/dmd.108.020834","article-title":"Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data","volume":"36","author":"Kilford","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib22","doi-asserted-by":"crossref","first-page":"100368","DOI":"10.1016\/j.dmpk.2020.11.003","article-title":"The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects","volume":"36","author":"Lee","year":"2021","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.123.001633_bib23","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1038\/psp.2014.18","article-title":"Evaluation of 4\u03b2-hydroxycholesterol as a clinical biomarker of CYP3A4 drug interactions using a Bayesian mechanism-based pharmacometric model","volume":"3","author":"Leil","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib24","first-page":"39","article-title":"Modeling and simulation of the endogenous CYP3A induction marker 4\u03b2-hydroxycholesterol during enasidenib treatment","volume":"11","author":"Li","year":"2019","journal-title":"Clin Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1124\/dmd.123.001633_bib26","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bdd.2359","article-title":"Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds","volume":"44","author":"Mao","year":"2023","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/dmd.123.001633_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","article-title":"Perspective: 4\u03b2-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A","volume":"49","author":"Mao","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.123.001633_bib28","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.gastro.2005.05.009","article-title":"Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans","volume":"129","author":"Marschall","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1124\/dmd.123.001633_bib29","doi-asserted-by":"crossref","first-page":"14721","DOI":"10.1021\/acs.jmedchem.2c01250","article-title":"Overcoming preclinical safety obstacles to discover (S)-N-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-6-(methylamino)-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-3-sulfonamide (GDC-2394): a potent and selective NLRP3 inhibitor","volume":"65","author":"McBride","year":"2022","journal-title":"J Med Chem"},{"key":"10.1124\/dmd.123.001633_bib30","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/molecules26040976","article-title":"NLRP3 inflammasome inhibitors in cardiovascular diseases","volume":"26","author":"Mezzaroma","year":"2021","journal-title":"Molecules"},{"key":"10.1124\/dmd.123.001633_bib31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1146\/annurev-med-080819-044918","article-title":"Treating coronary artery disease: beyond statins, ezetimibe, and PCSK9 inhibition","volume":"72","author":"Musunuru","year":"2021","journal-title":"Annu Rev Med"},{"key":"10.1124\/dmd.123.001633_bib32","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2165\/00003088-200847040-00004","article-title":"Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis","volume":"47","author":"Peters","year":"2008","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.123.001633_bib33","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1208\/s12248-022-00735-9","article-title":"Current approaches for predicting human PK for small molecule development candidates: findings from the IQ Human PK Prediction Working Group Survey","volume":"24","author":"Petersson","year":"2022","journal-title":"AAPS J"},{"key":"10.1124\/dmd.123.001633_bib34","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jps.10005","article-title":"Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution","volume":"91","author":"Poulin","year":"2002","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.123.001633_bib35","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/pds.3199","article-title":"Clinical importance of the drug interaction between statins and CYP3A4 inhibitors: a retrospective cohort study in The Health Improvement Network","volume":"21","author":"Rowan","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1124\/dmd.123.001633_bib36","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1124\/dmd.108.020602","article-title":"Modeling, prediction, and in vitro in vivo correlation of CYP3A4 induction","volume":"36","author":"Shou","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.123.001633_bib37","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41577-019-0165-0","article-title":"The NLRP3 inflammasome: molecular activation and regulation to therapeutics","volume":"19","author":"Swanson","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"10.1124\/dmd.123.001633_bib42","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1111\/cts.13576","article-title":"First-in-human phase 1 trial evaluating safety, pharmacokinetics, and pharmacodynamics of NLRP3 inflammasome inhibitor, GDC-2394, in healthy volunteers","volume":"16","author":"Tang","year":"2023","journal-title":"Clin Transl Sci"},{"key":"10.1124\/dmd.123.001633_bib38","doi-asserted-by":"crossref","first-page":"108053","DOI":"10.1016\/j.pharmthera.2021.108053","article-title":"Targeting the NLRP3 inflammasome in cardiovascular diseases","volume":"236","author":"Toldo","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.123.001633_bib39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/clpt.2009.72","article-title":"Plasma 4beta-hydroxycholesterol: an endogenous CYP3A metric?","volume":"86","author":"Tomalik-Scharte","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.123.001633_bib40","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1365-2125.2007.03078.x","article-title":"Time course of the increase in 4beta-hydroxycholesterol concentration during carbamazepine treatment of paediatric patients with epilepsy","volume":"65","author":"Wide","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.123.001633_bib41","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1124\/dmd.117.079210","article-title":"Quantitative analysis of complex drug-drug interactions between cerivastatin and metabolism\/transport inhibitors using physiologically based pharmacokinetic modeling","volume":"46","author":"Yao","year":"2018","journal-title":"Drug Metab Dispos"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624006640?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624006640?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.123.001633","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:48:33Z","timestamp":1743626913000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624006640"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S0090955624006640"],"URL":"https:\/\/doi.org\/10.1124\/dmd.123.001633","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Human Pharmacokinetic and CYP3A Drug\u2013Drug Interaction Prediction of GDC-2394 Using Physiologically Based Pharmacokinetic Modeling and Biomarker Assessment","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.123.001633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}